160 likes | 275 Views
A Promising Chemotherapy Agent, Gd@C82(OH)22. Ning Zhang Tianjin Medical University Cancer Institute and Hospital UICC 2008. Chemotherapies have always been accompanied with serious side effects. Can nanoparticles provide a new approach to design low toxic therapeutic agents?.
E N D
A Promising Chemotherapy Agent, Gd@C82(OH)22 Ning Zhang Tianjin Medical University Cancer Institute and Hospital UICC 2008
Chemotherapies have always been accompanied with serious side effects. Can nanoparticles provide a new approach to design low toxic therapeutic agents?
Treatments with Gd@C82(OH)22 Inhibit hepatoma growth in a mouse model 0.28 mg/kg 1.20mg/kg Gd@C82(OH)22 inhibits tumor growth in a breast tumor model. Nano Lett Vol 5, pg 2050
Treatments with Gd@C82(OH)22 induced a massive leukocyte infiltration in tumors.
Treatments with Gd@C82(OH)22 cancer cell chemotaxis and metastasis
Summary • Treatment with Gd@C82(OH)22 inhibits tumor growth without detectable toxicity. • 2. Gd@C82(OH)22 doesn’t show cytotoxicity. • 3. Gd@C82(OH)22 inhibits blood supply to tumor tissues. • 4. Gd@C82(OH)22 induced tumor immunity. • 5. Gd@C82(OH)22 inhibits cancer cell chemotaxis Blood supply Tumor immunity Metastasis
Chinese Academy Institute of High Energy Physics Tianjin Cancer Institute and Hospital National Center of Nanotechnology Research Center for Cancer Nanotechnology
Acknowledgements Dr. Yujie Ma Dr. Guoguang Ying Dr. Ruifang Niu Nanosafety Lab, Chinese Academy of Science Dr. Yuliang Zhao, Director Dr. Gengmei Xing Huan Meng Laboratory of Molecular Immunoregulation, NCI Dr. Joost Oppenheim, Chief Dr. De Yang
Gd@C82(OH)22 induced a dendritic cell to express CCR7 receptors HR (100 ug/ml)-treated DCs migrated to SLC but not Rantes, suggesting the HR-treated DCs were mature DCs.
T cell cytokine production in response to Gd@C82(OH)22-treated DCs
Treatments with Gd@C82(OH)22 disrupted the integrity of capillary blood vessels in tumors.